T-lymphoblastoid lymphoma has a current cure rate of between 30% and 70% after radiotherapy.
It is a kind of malignant lymphoma with high aggressiveness, accounting for 80% of lymphoblastic lymphoma, and belongs to different periods of the same disease with acute lymphoblastic leukemia, with poorer prognosis. It usually manifests as enlarged lymph nodes in the diaphragm and anterior mediastinum, or even compresses the trachea, esophagus, superior vena cava and so on, resulting in respiratory and swallowing difficulties, accompanied by systemic symptoms of lymphoma.
Clinical evaluation of its efficacy is divided into complete remission, partial remission, disease progression and disease stabilization. With the development of radiotherapy, the complete remission rate of this disease has been improved compared with the previous one, but the relapse rate is also high, which is an important cause of patient’s death, with the overall cure rate at 30%~70%, the complete remission rate after relapse at 30%~50%, and the 5-year overall survival rate at about 14%.
Specific therapeutic drugs include vincristine and cyclophosphamide, etc. Hematopoietic stem cell transplantation is commonly used in the treatment of relapsed and refractory patients, and specific diagnosis and treatment should be carried out under the guidance of physicians.